Reuters logo
BRIEF-U.S. FDA approves new combination treatment for acute myeloid leukemia
April 28, 2017 / 2:33 PM / 5 months ago

BRIEF-U.S. FDA approves new combination treatment for acute myeloid leukemia

April 28 (Reuters) - U.S. Food and Drug Administration :

* FDA approves new combination treatment for acute myeloid leukemia

* Says granted approval of Rydapt to Novartis Pharmaceuticals Corporation

* Approved Rydapt for treatment of adult patients with newly diagnosed acute myeloid leukemia with genetic mutation FLT3, in combination with chemotherapy

* Rydapt was also approved for adults with certain types of rare blood disorders

* Rydapt is approved for use with a companion diagnostic, LeukoStrat CDx FLT3 mutation assay

* Granted approval of LeukoStrat CDx FLT3 mutation assay to Invivoscribe Technologies Inc Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below